News

Insights into Rare Disease May Lead to Novel Therapeutic Targets for Parkinson’s

The rare lysosomal storage disorder Krabbe’s disease is caused by an enzyme deficiency and has been found to have surprising similarities with neurodegenerative disorders, including Parkinson’s disease. Establishing this connection can be a valuable tool for developing novel therapeutic targets and new biomarkers for identifying patients at risk for developing Parkinson’s.

New Therapy for Parkinson’s ‘Off’ Periods Shows Promising Results in Preclinical Studies

CVT-301, an inhalable drug under development by Acorda Therapeutics to treat Parkinson’s symptoms during “off” periods when currently available drugs don’t adequately work, showed promising results in preclinical Phase 1 and 2 studies. Since the late 1960s, levodopa has been the most common and efficient oral drug used for managing Parkinson’s motor…

Patent Request Filed for Cannabis-based Treatments for Parkinson’s and Like Diseases

Growblox Sciences has filed the first of several likely patent applications for cannabis-based compounds developed by Growblox Life Sciences, its wholly owned subsidiary. The application applies to pharmaceutical-grade mixtures that might be used to treat patients with neurodegeneration, especially those with Parkinson’s disease. Growblox Life Sciences is focused on researching and developing cannabis-based medicines.  The company uses various…

New Stem Cell Transplant System for Parkinson’s Disease Improves Cell Survival

Researchers using a new system with real-time imaging to guide transplants of neurons into the brains of non-human primate models with Parkinson’s Disease not only allowed better oversight of the procedure, but also improved cell survival. The research report, “Real-Time Intraoperative MRI Intracerebral Delivery of Induced Pluripotent Stem Cell-Derived Neurons,” published in…

Brain Stimulation for Parkinson’s Patients May Improve Slow, Rigid Movement

Treating Parkinson’s disease patients with high-frequency repetitive transcranial magnetic stimulation (rTMS) on both sides of the brain’s motor cortex improves bradykinesia (slow movement) and rigidity, according to a clinical trial analysis presented at the Fourth World Parkinson Congress, in Portland, Ore. The finding resulted from the analysis of a subset of patients from…